Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 34 Issue 4
. 
Turn off MathJax
Article Contents
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2016  >  34(4): 380-384

LIU Liu, FEI Sujuan. A Meta-analysis of Bifidobacterium viable triple capsule on Helicobacter pylori eradication during clinical therapy[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 380-384. doi: 10.3969/j.issn.1006-0111.2016.04.025
Citation: LIU Liu, FEI Sujuan. A Meta-analysis of Bifidobacterium viable triple capsule on Helicobacter pylori eradication during clinical therapy[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 380-384. doi: 10.3969/j.issn.1006-0111.2016.04.025
shu

A Meta-analysis of Bifidobacterium viable triple capsule on Helicobacter pylori eradication during clinical therapy

doi: 10.3969/j.issn.1006-0111.2016.04.025
  • 1.

    Xuzhou Medical College, Xuzhou 221002, China

  • 2.

    The Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China

  • Received Date: 2015-11-16
  • Rev Recd Date: 2016-05-10
  • Objective To evaluate the effecacy of Bifidobacterium viable triple capsule on anti-Helicobacter pylori (Hp) treatment and its adverse reactions during eradication therapy. Methods Trials on the effect of Bifidobacterium viable triple capsule on Hp eradication were analyzed by Meta-analysis with the software Stata 12.0 for comprehensive quantitative analysis of its clinical efficacy and adverse reactions during treatment. Results Eight randomly controlled trials (n=1144) were included. Pooled Hp eradication rates were 85.91% and 69.21% for patients with and without Bifidobacterium viable triple capsule respectively, with the odds ratio (OR) being 3.07 (95% CI=2.25~4.19, test for overall effect Z=7.08, P<0.01); the occurrences of total adverse reactions were 7.58% and 20.87% respectively, with the summary OR being 0.42 (95% CI=0.29~0.61, test for overall effect Z=4.48, P<0.01). The difference of the two groups was statistically significant. Conclusion Current evidence shows that Bifidobacterium viable triple capsule could increase eradication rate of anti-Hp treatment and improve adverse reactions during therapy.
  • [1] Jagusztyn-Krynicka EK, Godlewska R. New approaches for Helicobacter vaccine development-difficulties and progress[J]. Pol J Microbiol, 2008, 57(1):3-9.
    [2] Franceschi F, Gasbarrini A. Helicobacter pylori and extragas-tric diseasdes[J]. Best Pract Res Clin Gastroenterol, 2007, 21(2):325-334.
    [3] Sougioultzis S, Lee CK, Alsahi M, et al. Safety and efficacy of E.coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori[J]. Vaccine, 2002, 21(4):194-201.
    [4] 阎澜, 张军东. 培菲康临床应用进展[J]. 上海医药, 2007, 28(3):114-116.
    [5] Jadad A, Moore M, Carrol D, et al. Assessing the quality of reports of randomised clinical trials:is blinding necessary[J]. Control Clin Trials, 1996, 17(1):12-15.
    [6] 朱爱武. 培菲康对幽门螺杆菌感染慢性胃炎治疗的价值[J]. 现代诊断与治疗, 2012, 23(11):19-20.
    [7] 胡可伟, 张振玉, 刘顺英. 双歧杆菌三联活菌胶囊联合三联疗法根除幽门螺杆菌[J]. 临床荟萃, 2012, 27(7):610-611.
    [8] 黄继英, 曹海滨, 时宝忆. 培菲康联合标准三联疗法根除幽门螺杆菌疗效观察[J]. 上海医药, 2008, 29(12):552-554.
    [9] 彭栋柱, 王中原. 培菲康联合三联疗法根除幽门杆菌的临床观察[J]. 中国生化药物杂志, 2014, 34(2):147-148.
    [10] 钭慧敏. 双歧杆菌三联活菌胶囊联合三联疗法治疗幽门螺杆菌阳性消化性溃疡80例[J]. 中国药业, 2012, 21(23):49-50.
    [11] 檀心广, 米永刚, 杨杨. 培菲康对幽门螺杆菌感染慢性胃炎治疗的价值[J]. 海南医学, 2011, 22(19):25-26.
    [12] 沈芳, 李爽. 益生菌在根除幽门螺杆菌治疗中的价值[J]. 中国医药指南, 2010, 8(28):99-100.
    [13] 任珺, 郑京华, 魏虹. 培菲康联合四联疗法治疗难治性幽门螺杆菌感染54例疗效观察[J]. 海军医学杂志, 2013, 34(3):178-180.
    [14] 方积乾, 陆盈. 现代医学统计学[M]. 北京:人民卫生出版社, 2002, 150-209.
    [15] Glass GV. Primary, secondary, and meta analysis of research[J]. Education Research, 1976, 6(5):3-8.
    [16] Prieto G, Polanco I, Larraui J, et al. Helicobacter pylori in children:clinical endoscopic and histologic correlations[J]. Pediatr Gastroenterol Nutr, 1992, 14(5):420-425.
    [17] Valeur N, Engel P, Carbajal N, et al. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract[J]. Appl Environ Microbiol, 2004, 70(2):1176-1181.
    [18] Collado MC, Gonzalez A, Gonzalez R, et al. Antimicrobial peptides are among the antagonistic metabolites produced by Bifidobacterium against Helicobacter pylori[J]. Int J of Antimicrob Agents, 2005, 25(5):385-391.
    [19] 陈峰. 现代医学统计学方法与Stata应用[M]. 2版. 北京:中国统计出版社, 2003.
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(4129) PDF downloads(763) Cited by()

Related
Proportional views

A Meta-analysis of Bifidobacterium viable triple capsule on Helicobacter pylori eradication during clinical therapy

doi: 10.3969/j.issn.1006-0111.2016.04.025
  • 1. Xuzhou Medical College, Xuzhou 221002, China
  • 2. The Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China
  • Received Date: 2015-11-16
  • Rev Recd Date: 2016-05-10

Abstract: Objective To evaluate the effecacy of Bifidobacterium viable triple capsule on anti-Helicobacter pylori (Hp) treatment and its adverse reactions during eradication therapy. Methods Trials on the effect of Bifidobacterium viable triple capsule on Hp eradication were analyzed by Meta-analysis with the software Stata 12.0 for comprehensive quantitative analysis of its clinical efficacy and adverse reactions during treatment. Results Eight randomly controlled trials (n=1144) were included. Pooled Hp eradication rates were 85.91% and 69.21% for patients with and without Bifidobacterium viable triple capsule respectively, with the odds ratio (OR) being 3.07 (95% CI=2.25~4.19, test for overall effect Z=7.08, P<0.01); the occurrences of total adverse reactions were 7.58% and 20.87% respectively, with the summary OR being 0.42 (95% CI=0.29~0.61, test for overall effect Z=4.48, P<0.01). The difference of the two groups was statistically significant. Conclusion Current evidence shows that Bifidobacterium viable triple capsule could increase eradication rate of anti-Hp treatment and improve adverse reactions during therapy.

LIU Liu, FEI Sujuan. A Meta-analysis of Bifidobacterium viable triple capsule on Helicobacter pylori eradication during clinical therapy[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 380-384. doi: 10.3969/j.issn.1006-0111.2016.04.025
Citation: LIU Liu, FEI Sujuan. A Meta-analysis of Bifidobacterium viable triple capsule on Helicobacter pylori eradication during clinical therapy[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 380-384. doi: 10.3969/j.issn.1006-0111.2016.04.025
shu

    HTML

Reference (19)

Catalog

    版权所有：《药学实践与服务》编辑委员会

    Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

    Tel: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    Supported by: Beijing Renhe Information Technology Co., Ltd.  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return